Physicians' Academy for Cardiovascular Education

Are the COMPASS trial results applicable on a broader population in the REACH registry?

External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry

Literature - Darmon A, Bhatt DL, Elbez Y, et al. - Eur Heart J 2017; published online ahead of print

Main results

Conclusion

COMPASS-eligible patients represented a substantial part of the spectrum of stable CAD and PAD patients enrolled in the REACH registry. They had a higher risk of ischemic events compared with actual COMPASS participants in the aspirin alone treatment arm. These results should be interpreted with caution, due to important differences in the design between the 2 studies.

References

Show references

Find this article online at Eur Heart J

Share this page with your colleagues and friends: